Singapore: AusBiotech has appointed Mr Lawrence Gozlan as a non-executive director to its board. He has experience in global capital markets and is a specialist in life sciences investing. He holds a Bachelor of Science with honours in microbiology and immunology from the University of Melbourne, Australia, specializing in neurodegenerative diseases.

Mr Gozlan is the chief investment officer and founder of Scientia Capital, a specialised global investment fund focused exclusively in life sciences, which manages investments for institutional investors, family offices and high net worth individuals. Prior to this, Mr Gozlan was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at Queensland Investment Corporation (QIC), an investment fund with over $60 billion under management.

He also held the postion of senior biotechnology analyst at Foster Stockbroking, and advised numerous life sciences companies in corporate finance at Deloitte. Mr Gozlan is a board member of several public and private healthcare companies, and has presented at numerous international life science conferences.

AusBiotech chairman, Dr Deborah Rathjen, welcomed Mr Gozlan's appointment and said that his experience and background will be a great addition to the biotechnology industry's peak body. "It is a pleasure to welcome Lawrence to the AusBiotech Board. His deep experience in global biotech investing will be helpful in bringing forward new initiatives targeting investment into Australian companies," Dr Rathjen added.

Mr Gozlan was pleased to accept the appointment and said that, "I am delighted to join the board of AusBiotech during this exciting time in the Australian life sciences industry. By assuming this role, I look forward to helping advance policies that will enable people around the world to benefit from the work that Australian companies carry out."